Dr. Garakani is a former Attending Psychiatrist at Mount Sinai Hospital. He is currently a full-time Attending Psychiatrist at Silver Hill Hospital in New Canaan, CT. He also maintains a small private practice in both New Canaan and New York City. He is Board-Certified in Psychiatry, Forensic Psychiatry and Addiction Medicine. He received his B.A. in Classics (Latin), cum laude, with Distinction in All Subjects, from Cornell University, and his M.D. from the SUNY Upstate Medical University in Syracuse, NY, where he won the AMA Rock Sleyster Scholarship. He completed his residency at the Mount Sinai Medical Center and a research fellowship at the Mood and Anxiety Disorders Program at the Mount Sinai School of Medicine. Dr. Garakani also completed a fellowship in Forensic Psychiatry at New York University Medical Center. He has won several awards including the American Psychiatric Association (APA)/Lilly Resident Research Award, APA – NY County District Branch Resident Research Award, and travel awards from the Anxiety Disorders Association of America and Society of Biological Psychiatry. He also was an APA/GlaxoSmithKline Fellow and a Fellow of the Group of the Advancement of Psychiatry. He has participated in NIMH-funded research and is first or co-author on over 40 peer-reviewed papers and book chapters. He teaches classes to Mount Sinai residents on psychopharmacology and forensic psychiatry and is a supervisor to psychiatry residents and medical students. He previously was elected to the Executive Council of the APA NY County District Branch. He is a Distinguished Fellow of the American Psychiatric Association and a recent Member-Elect of the American College of Psychiatrists.
- Generalized Anxiety Disorder
- Panic Disorder
- Post-Traumatic Stress Disorder
- Social Anxiety Disorder
BA, Cornell University
Fellowship, New York University Medical Center
MD, SUNY Upstate Medical University
Residency, Mount Sinai Medical Center
Garakani A, Shalenberg E, Burstin SC, Weintraub Brendel R, Appel JM. Voluntary psychiatric hospitalization and patient-driven requests for discharge: a statutory review and analysis of implications for the capacity to consent to voluntary hospitalization. Harvard Review of Psychiatry 2014; 22(4): 241-249.
Goldberg JF, Garakani A, Ackerman SH. Clinician- versus self-rated screening for bipolar disorder among inpatients with mood symptoms and substance abuse. J Clin Psychiatry 2012; 73(12): 1525–1530.
Garakani A, Martinez JM, Yehuda R, Gorman JM. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. Journal of Affective Disorders 2013 Apr; 146(2): 262-265.
Krystal JH, Mathew SJ, D’Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor glutamate receptor agonists and antagonists. CNS Drugs 2010; 24(8): 669-693.
Garakani A, Buchsbaum MS, Newmark RE, Goodman C, Aaronson CJ, Martinez JM, Torosjan Y, Chu K, Gorman JM. The effect of doxapram on brain imaging in patients with panic disorder. European Neuropsychopharmacology 2007; 17(10): 672-686.
Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatments. Mount Sinai Journal of Medicine 2006; 73(7): 941-949.
Hirschowitz J, Kolevzon A, Garakani A. The pharmacological treatment of bipolar disorder: the question of modern advances. Harvard review of psychiatry 266-278; 18(5).
Garakani A, Martinez JM, Aaronson CJ, Voustianiouk A, Kaufmann H, Gorman JM. Effect of medication and psychotherapy on heart rate variability in panic disorder. Depression and Anxiety 2009; 26(3): 251-258.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Garakani did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.